ResMed Launches NightOwl™ Home Sleep Apnea Test Across the U.S.

ResMed has announced the nationwide availability of its FDA-cleared home sleep apnea test, NightOwl™, across the United States. Designed for ease of use and clinical accuracy, NightOwl enables individuals to conduct sleep apnea testing at home using a small fingertip sensor and a smartphone.

The device records up to ten nights of sleep data and sends it to a cloud-based platform for physician review, helping streamline the diagnostic process for obstructive sleep apnea (OSA), a condition affecting nearly one billion people worldwide. Key features include auto-scored results, integration with ResMed’s Somnoware platform, and full disposability, eliminating the need for returns or cleaning.

NightOwl uses peripheral arterial tonometry technology and has demonstrated diagnostic accuracy in clinical validation studies. ResMed emphasizes that the test makes OSA screening more accessible and supports the company’s mission of delivering home-based, life-changing healthcare technology.

NightOwl is now available nationwide. Interested individuals should consult their healthcare provider or visit ResMed’s website for more information.

ResMed Inc. reported strong financial results for the second quarter of fiscal year 2025, driven by increased demand for its sleep and breathing health products and digital health solutions. Revenue increased by 10% year-over-year to $1.3 billion, with a 10% rise on a constant currency basis. Gross margin improved to 58.6%, reflecting manufacturing efficiencies and lower component costs.

Operating income rose significantly by 52%, while non-GAAP income from operations increased by 19%. Net income surged 65% to $345 million, with diluted earnings per share rising to $2.34. Non-GAAP net income grew 29% to $358 million, with non-GAAP diluted EPS at $2.43. Operating cash flow for the quarter was a robust $309 million.

ResMed highlighted strong regional performance, with revenue in the U.S., Canada, and Latin America (excluding Residential Care Software) growing by 12%, while revenue in Europe, Asia, and other markets increased by 8% on a constant currency basis. Residential Care Software revenue also grew by 8%.

During the quarter, ResMed repurchased 307,000 shares for $75 million and paid $78 million in dividends. The company reaffirmed its commitment to expanding operations in Singapore and continued its focus on digital health innovations.

A quarterly cash dividend of $0.53 per share was declared, payable on March 20, 2025, with a record date of February 13, 2025.